Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma

Current Medicinal Chemistry
Mattia D'AgostinoFrancesca Gay

Abstract

Survival of multiple myeloma patients has considerably improved in the last decades thanks to the introduction of many new drugs, including immunomodulatory agents, proteasome inhibitors and, more recently, monoclonal antibodies. We analyzed the most recent literature focusing on the clinical and pharmacologic aspects of monoclonal antibody-based therapies in multiple myeloma, including monoclonal antibodies directed against plasma cell antigens, as well as checkpoint blockade therapy directed against immune inhibitory molecules, used as single agents or in combination therapy. Anti-CD38 monoclonal antibodies including daratumumab, isatuximab and MOR202 have shown outstanding results in relapsed and/or refractory multiple myeloma patients. The addition of daratumumab to bortezomib-dexamethasone or lenalidomidedexamethasone substantially improved patients' outcome in this patient population. The anti- SLAMF7 molecule elotuzumab in combination with lenalidomide-dexamethasone showed to be superior to lenalidomide-dexamethasone alone, without adding meaningful toxicity. Checkpoint blockade therapy in combination with immunomodulatory agents produced objective responses in more than 50% of treated patients. However, this combination...Continue Reading

References

Jan 4, 2001·Leukemia Research·S DeaglioF Malavasi
Feb 27, 2001·Nature Immunology·Y LatchmanG J Freeman
Apr 15, 2004·American Journal of Clinical Pathology·Pei LinCarla S Wilson
Aug 17, 2004·The Journal of Allergy and Clinical Immunology·Michael I KotlikoffPrescott G Woodruff
Feb 6, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tomonori TawaraShiro Kataoka
Jan 20, 2009·Nature Immunology·Mario-Ernesto Cruz-MunozAndré Veillette
May 12, 2009·Immunological Reviews·James L Riley
Dec 17, 2009·Cell Research·Jason R Dunkelberger, Wen-Chao Song
Jan 9, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Diane R Mould, Bruce Green
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Dec 29, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michel de WeersPaul W H I Parren
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sagar LonialSundar Jagannath
May 5, 2012·World Journal of Biological Chemistry·Yulia VugmeysterMichael W Leach
Jun 5, 2013·Critical Reviews in Oncology/hematology·André Veillette, Huaijian Guo
Jul 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jutta DeckertVéronique Blanc
Jul 12, 2014·BioMed Research International·Alessandra RomanoFrancesco Di Raimondo
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Aug 27, 2015·The New England Journal of Medicine·Henk M LokhorstPaul G Richardson
Feb 13, 2016·Immunological Reviews·Niels W C J van de DonkPaul W H I Parren
Feb 24, 2016·Pediatric Hematology and Oncology·A R GigliottiC Gandolfo
Mar 20, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Leonid GibianskyManish Gupta
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander M LesokhinJohn Timmerman
Aug 25, 2016·The New England Journal of Medicine·Antonio PalumboUNKNOWN CASTOR Investigators
Aug 26, 2016·Hospital Pharmacy·J Aubrey Waddell, Dominic A Solimando
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Dec 9, 2016·Investigational New Drugs·Noboru YamamotoTomohide Tamura
Dec 27, 2016·CPT: Pharmacometrics & Systems Pharmacology·G BajajY Feng
Apr 28, 2017·Expert Opinion on Investigational Drugs·Mattia D'AgostinoFrancesca Gay
May 19, 2017·Journal for Immunotherapy of Cancer·Tomoko FreshwaterJulie A Stone

❮ Previous
Next ❯

Citations

Nov 6, 2018·Expert Opinion on Biological Therapy·Francesca BonelloFrancesca Gay
Nov 4, 2020·International Journal of Molecular Sciences·Mattia D'AgostinoSara Bringhen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Expert Review of Clinical Immunology
Jean-Samuel BoudreaultPhilippe Moreau
Expert Review of Clinical Immunology
Kristine A FrerichsNiels W C J van de Donk
Expert Review of Hematology
Sonja Genadieva StavricAlessandra Larocca
© 2022 Meta ULC. All rights reserved